Aurion Biotech, Inc. (AURN)
Aurion Biotech will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Aurion Biotech Statistics
Total Valuation
Market Cap | n/a |
Enterprise Value | n/a |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | n/a |
Shares Outstanding | n/a |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | n/a |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
Current Ratio | n/a |
Quick Ratio | 3.54 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | 55.48 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Invested Capital (ROIC) | n/a |
Return on Capital Employed (ROCE) | n/a |
Revenue Per Employee | $9,522 |
Profits Per Employee | -$868,377 |
Employee Count | 69 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, Aurion Biotech has paid $42,000 in taxes.
Income Tax | 42,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | n/a |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | n/a |
Average Volume (20 Days) | n/a |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Aurion Biotech had revenue of $657,000 and -$59.92 million in losses.
Revenue | 657,000 |
Gross Profit | -997,000 |
Operating Income | -60.37M |
Pretax Income | -59.88M |
Net Income | -59.92M |
EBITDA | -60.28M |
EBIT | -60.98M |
Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has $52.07 million in cash and $62.55 million in debt, giving a net cash position of -$10.49 million.
Cash & Cash Equivalents | 52.07M |
Total Debt | 62.55M |
Net Cash | -10.49M |
Net Cash Per Share | n/a |
Equity (Book Value) | -220.54M |
Book Value Per Share | n/a |
Working Capital | 39.67M |
Cash Flow
In the last 12 months, operating cash flow was -$51.88 million and capital expenditures -$786,000, giving a free cash flow of -$52.67 million.
Operating Cash Flow | -51.88M |
Capital Expenditures | -786,000 |
Free Cash Flow | -52.67M |
FCF Per Share | n/a |
Margins
Gross margin is -151.75%, with operating and profit margins of -9,189.19% and -9,119.94%.
Gross Margin | -151.75% |
Operating Margin | -9,189.19% |
Pretax Margin | -9,113.55% |
Profit Margin | -9,119.94% |
EBITDA Margin | -9,174.28% |
EBIT Margin | -9,280.82% |
FCF Margin | -8,016.59% |
Dividends & Yields
Aurion Biotech does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |